Starpharma Holdings Share Price and Company Fundamentals



Price
$1.68
Change
-0.040 (-2.326%)
52 week
0.8 - 2.52

Last traded: Today at 5:04 AM

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Key Metrics

PE ratio

-

PB ratio

9.77

Dividend yield

Beta

1.31

Market cap

$682.21M

Enterprise value

$688.44M

Company profile

Primary activitiesBiotechnology - development of dendrimer technology for pharmaceutical, life science and other applications.
Industry / SectorBiotechnology / Healthcare
Websitehttp://starpharma.com
Mailing address4-6 Southampton Crescent Abbotsford VIC 3067 Australia
Phone / Fax61 3 8532 2700 / 61 3 9510 5955
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Starpharma Holdings does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Starpharma Holdings.

NameTitleAgeTotal Pay
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICDCEO, MD & Exec. Director57579.15k
Mr. Nigel J. Baade B.Com, Grad. Dip., CPACFO & Company Sec.283.08k

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-1,343.66%

Return on assets

-20.52%

Return on equity

-35.69%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Starpharma Holdings is 682.21M and its enterprise value is 688.44M. The enterprise value to revenue ratio of SPL is 452.03.

The SPL's stocks Beta value is 1.31 making it 31% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Starpharma Holdings (SPL)

Starpharma Holdings (ASX:SPL) Frequently Asked Questions

1. What is Starpharma Holdings's Stock Symbol?

Starpharma Holdings trades on ASX under the ticker symbol "SPL".

2. What is Starpharma Holdings's stock price today?

One share of SPL stock can currently be purchased for approximately $1.68.

3. How can I contact Starpharma Holdings?

Starpharma Holdings's mailing address is 4-6 Southampton Crescent Abbotsford VIC 3067 Australia. The company can be reached via phone at 61 3 8532 2700.

4. What is Starpharma Holdings's official website?

The official website of Starpharma Holdings is http://starpharma.com.

5. Which share registry manages Starpharma Holdings's stock?

Starpharma Holdings's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.